The EU backed Innovative Medicines Initiative has updated its strategic research agenda, outlining strategies to overcome 'bottlenecks' to efficient R&D for new medicines.
Cambridge Antibody Technology Group Plc, which is traded on both the LSE and Nasdaq markets, said an agreement was struck at the 11th hour over a royalty dispute with Abbott Laboratories Inc.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.